Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Apollomics

Request full access

An innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies

Foster City, United StatesFounded 2016Biotech & Life Sciences

About Apollomics

Apollomics is a biotechnology company focused on the discovery and development of oncology combination therapies. Operating in both the U.S. and China, the company leverages partnerships with other biotechnology firms to enhance its capabilities. Founded in 2015, Apollomics has built a pipeline of ten drug candidates across 12 programs, with five candidates at the clinical stage. The pipeline is categorized into three groups based on mechanisms of action: tumor inhibitors, anti-cancer enhancers, and immuno-oncology drugs. Tumor inhibitors include small molecule inhibitors targeting uncontrolled growth signaling pathways, with a c-Met inhibitor as the core product. Anti-cancer enhancers are designed to boost the efficacy of other treatments and include antagonists developed as adjuncts to chemotherapy. Immuno-oncology drugs utilize the body's immune system to combat cancer, featuring mono-specific and bi-specific antibodies and a novel cancer vaccine. Apollomics aims to develop synergistic combination therapies to address unmet needs in cancer treatment.

Source: Dealroom company data

At a glance

Status
Operational
Employees
24
Open positions
None listed
Dealroom signal
72.8/100
Industry
Health
Sub-industry
BioTechnology
Sector
Alternative Medicine, Biotechnology, Oncology, Immune System, Spinout, Biotech and Pharma, SPAC Target, SPAC IPO Announced, DT and LS, UKSU
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Jan 2019
Capital deployed
$59M
Preferred round
SERIES A

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO DEBTDebt Mar 2026 $2M — Undisclosed ↗
PRIVATE PLACEMENT VCOther financing May 2024 $6M — Undisclosed ↗
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Apollomics website traffic

Latest recorded traffic for Apollomics is 2.6K monthly website visits, up 0% over the last three months. Apollomics's team declined 11.1% over the past year.

Latest monthly visits2.6K 3-month web change0% 1-year team growth-11.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Apollomics in the Foster City ecosystem

Live from Dealroom

The Apollomics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

Series B and later3 investors entered at this stage

  • Ping An Capital
  • Ping An Group
  • Maxpro Capital Acquisition Corp

Other known investors1 additional known investor

  • University of Nottingham
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Apollomics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.